CagriSema vs Semaglutide: price and facts compared (2026)
Neither product has an in-stock offer right now.
| CagriSema | Semaglutide | |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Standard size | 10/10mg | 10mg |
| All sizes | 5/5mg, 10/10mg | 5mg, 10mg, 20mg |
| Cheapest now | Not in stock | Not in stock |
| Price per mg | Priced as a set | Priced as a set |
| Vendors | 0 | 0 |
| Forms | Vial | Vial |
| Regulatory status | Investigational · phase 3 (Novo Nordisk). Not approved for human use. | FDA-approved as Ozempic (2017) and Wegovy (2021). The research vial is not the approved product. |
| Stock | Out of stock | Out of stock |
CagriSema is a co-formulation of cagrilintide and semaglutide developed by Novo Nordisk and studied in phase 3 obesity trials. Research vendors sell the two peptides co-lyophilized in 5/5 mg and 10/10 mg vials.
CagriSema prices →Semaglutide is a GLP-1 receptor agonist peptide and the active compound in Ozempic and Wegovy. Research vendors sell it lyophilized in 5–20 mg vials.
Semaglutide prices →Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. Prices include a discount only when the offer shows a code, and exclude shipping. Stock status is captured at the same time. Rankings are by price only. PeptideTech earns a commission when you buy through a link; it never changes the order.
Full method →